Latest Breaking News On - Kinase inhibitor - Page 3 : comparemela.com

Using ripretinib and surgery to manage recurrent gastrointestinal stromal tumor

A new case report was published in Oncoscience (Volume 10) on September 20, 2023, entitled, "Multi-disciplinary management of recurrent gastrointestinal stromal tumor harboring KIT exon 11 mutation with the switch-control kinase inhibitor ripretinib and surgery."

United statesFilip jankuVivek subbiahNeeta somaiahDanielle ellisSireesha yedururiUniversity of texas md anderson cancer centerSarah cannon research instituteCancer centerKinase inhibitor

ORIC Pharmaceuticals to Present Initial Phase 1b Clinical Data for ORIC 114 in EGFR/HER2 Exon 20 Mutated NSCLC at the European Society of Medical Oncology (ESMO) Congress 2023

17.10.2023 - Company to host a conference call and webcast on Saturday, October 21, 2023, at 9:00 am ET featuring Dr. Alexander Spira to discuss initial data and potential of ORIC-114 in EGFR/HER2 mutated cancersSOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Oct. .

United statesSouth san franciscoSan diegoAlexander spiraPharmaceuticals incGlobal phaseHighly selectiveBrain penetrantAdvanced solid tumors harboringKinase inhibitorAgainst atypical mutationsOvercoming resistanceOric pharmaceuticals chartRic pharmaceuticals kursRic pharmaceuticals aktie

ORIC Pharmaceuticals to Present Initial Phase 1b Clinical Data for ORIC 114 in EGFR/HER2 Exon 20 Mutated NSCLC at the European Society of Medical Oncology (ESMO) Congress 2023

Company to host a conference call and webcast on Saturday, October 21, 2023, at 9:00 am ET featuring Dr. Alexander Spira to discuss initial data and potential of ORIC-114 in EGFR/HER2 mutated.

United statesSouth san franciscoSan diegoAlexander spiraDominic piscitelliPharmaceuticals incEuropean society of medical oncologyEuropean societyMedical oncologyClinical directorGlobal phaseHighly selectiveBrain penetrantAdvanced solid tumors harboringKinase inhibitorAgainst atypical mutations

ORIC Pharmaceuticals to Present Initial Phase 1b Clinical Data for ORIC 114 in EGFR/HER2 Exon 20 Mutated NSCLC at the European Society of Medical Oncology (ESMO) Congress 2023

ORIC Pharmaceuticals to Present Initial Phase 1b Clinical Data for ORIC 114 in EGFR/HER2 Exon 20 Mutated NSCLC at the European Society of Medical Oncology (ESMO) Congress 2023
tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.

San diegoUnited statesSouth san franciscoDominic piscitelliAlexander spiraPharmaceuticals incPharmaceuticals to present initial phaseEuropean society of medical oncologyPresent initial phaseClinical dataEuropean societyMedical oncologyClinical directorGlobal phaseHighly selectiveBrain penetrant

TAGRISSO® Plus Chemotherapy Granted Priority Review in the US for Patients with EGFR-Mutated Advanced Lung Cancer

WILMINGTON, Del. (BUSINESS WIRE) Oct 16, 2023

United kingdomUnited statesSusan galbraithBrendan mcevoyDaiichi sankyoChelsea fordWorld health organisationInternational agency for research on cancerLungevity foundationSingle institution studyLung ambition allianceDrug administrationNew drug applicationPriority reviewPrescription drug user fee actExecutive vice president